# Henan Zhenshi Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/henan-zhenshi-biotechnology

- Industry: Biotechnology
- Headquarters: Pingdingshan, China
- Total disclosed funding: $100M
- Latest round: Series B (Aug 27, 2021)
- Investors on record: 5

## About

Established in 2012 and based in Pingdingshan, China, Henan Zhenshi Biotechnology operates as an innovative drug developer that focuses on anti-acquired immune deficiency syndrome (AIDS) drugs.

The company provides the research and development, production and sales of innovative drug. The product of the company includes azivudine tablets. The company develops innovative drug about anti-virus, anti-tumor, cardiovascular and cerebrovascular and liver diseases.

The company will start Hong Kong stock initial public offering (IPO).

## Funding rounds

- Series B, Aug 27, 2021, $100M — ABC Capital, Desano Pharma, Efung Capital, Yingke Private Equity, Shanghai Fuze Investment

## Investors

- ABC Capital (https://capitalatlas.ai/funds/abc-capital) — Series B
- Desano Pharma — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series B
- Shanghai Fuze Investment — Series B